BusinessAbeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102By Nasdaq OMXSep 28, 2017, 12:32 PM UTC
BusinessAbeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis BullosaBy Nasdaq OMXAug 29, 2017, 1:05 PM UTC
BusinessAbeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017By Nasdaq OMXAug 17, 2017, 1:15 PM UTC
BusinessAbeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis BullosaBy Nasdaq OMXJul 18, 2017, 12:05 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy ProgramBy Nasdaq OMXJun 29, 2017, 12:15 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
